Viatris (1VTRS) AI Stock Analysis

Company Guidance

For 2026, excluding contributions from the proposed acquisition of Pacira, Viatris expects at the midpoint of its revised guidance ranges operational growth of approximately 2% for total revenues, 6% for adjusted EBITDA and 8% for adjusted EPS versus the prior year; by region, North America is expected to be in the high single-digit range, Europe flattish, emerging markets and JANZ low single-digit declines, and Greater China closer to the low double-digit range, while fourth-quarter supply disruptions are expected to impact total revenues by approximately $100 million, and net savings from the strategic review are expected to reach $120 million this year. Viatris expects the Pacira transaction to close before the end of November, be immediately accretive to all financial guidance metrics in 2027 versus expected 2026 results, generate more than $50 million in annual cost synergies by the end of 2028, and help its U.S. innovative medicines business generate more than $1 billion in total revenue in 2027; Greater China is expected to grow in 2027, albeit closer to historical averages in the low to mid-single-digit range, and the company expects its patches to reach 1.5 million women in 2026 and add in 2027 another 1 million of women using its patches.